Davis Polk & Wardwell advised the several initial purchasers on the offering. Immunocore Holdings plc (Immunocore) (Nasdaq: IMCR) announced the pricing of $350.0 million aggregate principal amount...
Immunocore Holdings’ $402.5 Million Convertible Notes Offering
Immunocore’s $250 Million At-The-Market Offering
Davis Polk advised Jefferies, the sales agent, in the offering. Immunocore Holdings plc announced the SEC-registered at-the-marketing offering program of its American depositary shares (ADSs) representing its ordinary...
Vaccitech’s $75 Million At-The-Market Offering
Davis Polk advised the sales agent Jefferies in the offering. Vaccitech plc executed an at-the-marketing offering program of its American depositary shares representing its ordinary shares under...
LivaNova’s $345 Million Equity Offering
Cleary Gottlieb Steen & Hamilton represented LivaNova, while Davis Polk advised the representatives of the several underwriters in the offering. LivaNova PLC executed its offering of 4,181,818 ordinary...
Royalty Pharma’s $1.3 Billion Senior Notes Offering
Davis Polk advised Royalty Pharma plc on the transaction. Royalty Pharma executed its offering of $1.3 billion aggregate principal amount of senior notes. The offering consisted of...
Membership Collective Group’s US$420 Million IPO
Sidley Austin LLP advised Membership Collective Group Inc. on the deal, while Davis Polk advised the underwriters. Membership Collective Group (“MCG”), a global membership platform comprised...
Tencent Holdings Limited’s GBP919 Million Recommended Cash Acquisition of Sumo Group plc
Allen & Overy advised Sumo Group plc on the deal, while Davis Polk advised Tencent Holdings Limited. Tencent Holdings Limited made an all cash acquisition through its indirect...
Vaccitech’s $110.5 Million Initial Public Offering
Goodwin Procter LLP advised Vaccitech on the deal, while Davis Polk advised the representatives of the several underwriters. Vaccitech (Nasdaq: VACC) announced its initial public offering...